Axcella Health  logo
Axcella Health AXLA

Quarterly report 2023-Q2
added 08-03-2023

report update icon

Axcella Health Net Debt 2011-2026 | AXLA

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Axcella Health

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.5 M -46.4 M -67.2 M -54.9 M -27.3 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.5 M -67.2 M -38.8 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
ADMA Biologics ADMA Biologics
ADMA
-17.2 M $ 15.6 -5.71 % $ 3.72 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.55 -2.34 % $ 1.06 B canadaCanada
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.82 -0.73 % $ 4.47 M chinaChina
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-311 M $ 20.14 1.41 % $ 2.54 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
166 M $ 75.28 -1.63 % $ 1.45 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-49.4 M - - $ 8.42 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.47 -9.81 % $ 375 M britainBritain
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Athersys Athersys
ATHX
-27.6 M - 3.77 % $ 22.4 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-48 M - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 160.48 -2.19 % $ 7.98 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
1.44 B $ 65.44 -1.65 % $ 12.5 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
533 K - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
-33.1 M - -4.8 % $ 255 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
-3.56 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
-34.7 M - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
-60.5 M - -7.31 % $ 87 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-23.8 M - -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
-13.9 M $ 2.75 -2.14 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
-1.3 B $ 60.53 0.17 % $ 11.6 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 8.26 -1.37 % $ 1.36 B britainBritain
Cabaletta Bio Cabaletta Bio
CABA
-188 M $ 3.19 -7.14 % $ 3.73 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
-60.8 M $ 2.98 -7.03 % $ 1.07 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Capricor Therapeutics Capricor Therapeutics
CAPR
-12.5 M $ 25.34 -0.65 % $ 679 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
-114 M $ 34.35 -3.75 % $ 3.57 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
263 K $ 8.02 -4.75 % $ 34.7 M usaUSA